Bautista-Mondragón CA, Mijangos-Trejo AM, González-Chon O, Mondragón-Ratkovich P, Chávez-Tapia NC. Predictors of mortality and liver transplant requirement in patients with hepatitis A virus: A case series from Mexico. World J Gastrointest Surg 2026; 18(1): 112767 [DOI: 10.4240/wjgs.v18.i1.112767]
Corresponding Author of This Article
Norberto Carlos Chávez-Tapia, MD, Gastroenterology and Obesity Unit, Medica Sur Clinic, Puente de Piedra No. 150, Mexico City 14050, Ciudad de México, Mexico. n.chaveztapia@pm.me
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jan 27, 2026 (publication date) through Jan 28, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Surgery
ISSN
1948-9366
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Bautista-Mondragón CA, Mijangos-Trejo AM, González-Chon O, Mondragón-Ratkovich P, Chávez-Tapia NC. Predictors of mortality and liver transplant requirement in patients with hepatitis A virus: A case series from Mexico. World J Gastrointest Surg 2026; 18(1): 112767 [DOI: 10.4240/wjgs.v18.i1.112767]
World J Gastrointest Surg. Jan 27, 2026; 18(1): 112767 Published online Jan 27, 2026. doi: 10.4240/wjgs.v18.i1.112767
Predictors of mortality and liver transplant requirement in patients with hepatitis A virus: A case series from Mexico
Cristian Alejandro Bautista-Mondragón, Alejandra Madeleine Mijangos-Trejo, Octavio González-Chon, Pablo Mondragón-Ratkovich, Norberto Carlos Chávez-Tapia
Cristian Alejandro Bautista-Mondragón, Pablo Mondragón-Ratkovich, Department of Internal Medicine, Medica Sur Clinic, Mexico City 14050, Ciudad de México, Mexico
Alejandra Madeleine Mijangos-Trejo, Norberto Carlos Chávez-Tapia, Gastroenterology and Obesity Unit, Medica Sur Clinic, Mexico City 14050, Ciudad de México, Mexico
Octavio González-Chon, Medica Sur Clinic, Mexico City 14050, Ciudad de México, Mexico
Author contributions: Bautista-Mondragón CA and Mondragón-Ratkovich P contributed to the data collection, processing, and analysis; Mijangos-Trejo AM and Chávez-Tapia NC validated and reviewed the information used in the theoretical framework; Mijangos-Trejo AM, González-Chon O, and Chávez-Tapia NC supervised database creation and analysis; Bautista-Mondragón CA conducted the literature review, protocol development, and prepared the final report for dissemination; Chávez-Tapia NC ensured the reliability of laboratory results and prognostic scales; González-Chon O validated and reviewed the theoretical framework, and provided statistical guidance.
Institutional review board statement: This study was reviewed and approved by the Research Ethics Committee of Medica Sur Clinic (CONBIOETICA-09-CEI-018-20160729). The study was conducted in accordance with the Declaration of Helsinki and institutional guidelines.
Informed consent statement: Because of the retrospective design, the requirement for informed consent was waived by the Research Ethics Committee. All patient data were anonymized and handled with strict confidentiality.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated and/or analyzed during the current study are not publicly available due to institutional data protection policies but are available from the corresponding author on reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Norberto Carlos Chávez-Tapia, MD, Gastroenterology and Obesity Unit, Medica Sur Clinic, Puente de Piedra No. 150, Mexico City 14050, Ciudad de México, Mexico. n.chaveztapia@pm.me
Received: August 6, 2025 Revised: September 23, 2025 Accepted: November 10, 2025 Published online: January 27, 2026 Processing time: 169 Days and 6.2 Hours
Abstract
BACKGROUND
Hepatitis A virus (HAV) infection remains a significant cause of acute viral hepatitis globally, and the endemicity pattern is intermediate in Mexico. Although most cases follow a benign and self-limited course, less than 5% of patients with HAV infection progress to acute liver failure, which carries mortality rates of 13%-33% depending on access to liver transplantation (LT). The identification of clinical and biochemical predictors of adverse outcomes is crucial to improve early risk stratification, optimize patient management, and guide timely referral to transplant centers.
AIM
To assess the utility of clinical and biochemical variables and prognostic scores in predicting mortality and the need for LT in patients with acute HAV infection.
METHODS
We conducted a retrospective case series of all patients hospitalized at Medica Sur Clinic between 2018 and 2024 who were positive for immunoglobulin M antibodies for HAV. Clinical and laboratory data were collected from patients’ electronic medical records. Continuous variables were summarized as the means ± SD or median and interquartile range and compared using Student’s t-test or the Mann-Whitney U test, as appropriate. Categorical variables were expressed as frequencies and percentages and compared using the χ2 test or Fisher’s exact test.
RESULTS
A total of 69 patients with HAV infection (mean age, 38 ± 11 years; 65% male) were included. 14% of patients had a history of hepatic steatosis, 10% had type 2 diabetes, and 45% were smokers. Acute liver injury was observed in 47 patients (68%), acute liver failure was detected in five patients (7.2%), and mortality or LT occurred in three patients (4.3%; two deaths and one transplant). Patients who died or required orthotopic LT were older, and they had higher heart and respiratory rates at admission. These patients additionally exhibited greater liver dysfunction, including higher bilirubin and transaminase levels, prolonged coagulation times, lower sodium and albumin levels, and worse albumin-bilirubin scores. Severity scores [model for end-stage liver disease (MELD), MELD with sodium, MELD version 3.0] were significantly higher in patients with complications than in those without complications.
CONCLUSION
Advanced age, elevated severity, and higher albumin-bilirubin scores emerged as predictors of adverse outcomes in patients with HAV infection, and consideration of these factors could guide the need for more intensive monitoring strategies. These findings highlight the importance of incorporating prognostic scoring systems into routine clinical evaluation to improve outcomes in high-risk patients.
Core Tip: Hepatitis A virus infection is among the most common causes of acute viral hepatitis globally. Predicting the clinical course of hepatitis A virus infection remains challenging. Risk factors such as encephalopathy, leukocytosis, acute kidney injury, hypoalbuminemia, and hyperbilirubinemia can be used to identify patients at risk for developing acute liver failure. Previously, we reported a fulminant hepatitis incidence of 0.3%, which increased to 1.8% in individuals older than 49 years, with serum creatinine level > 2 mg/dL being the strongest predictor of fulminant hepatitis or mortality. Given the epidemiological transition of this disease in Mexico, updated data are crucial.